Canada's Xenon touts out-of-the-blue win for its daily epilepsy pill, sending investors into a frenzy
Looking to shake up the market for seizure and epilepsy patients, Xenon Pharmaceuticals reported new topline data Monday that earned a ringing endorsement from investors.
The British Columbia-based biotech revealed its XEN1101 program passed a Phase IIb test at all three doses, producing highly statistically significant results at the mid-and high-dose levels. There’s no concrete plan yet to commercialize the drug, as Xenon still needs to meet with the FDA, but the biotech noted it expanded the study’s open-label extension to three years to obtain more follow-up data.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
